We sat down with Scotch McClure of @MaxwellBiosci to talk about disease prevention, reversing aging, and the future of health. This interview will change how you think about aging:

Synthetic immune systems could be the next big breakthrough in biotech. Hear from Scotch McClure, CEO of @MaxwellBiosci, on how they're leading the charge. Watch now:

The future of health might lie in our microbiome. Learn how Scotch McClure and @MaxwellBiosci are unlocking the secrets to a longer, healthier life

What if we could replace antibiotics and antivirals with one solution? Scotch McClure from @MaxwellBiosci explores this exciting future in our latest interview:

Is reversing aging the next big biotech breakthrough? Hear from Scotch McClure, CEO of @MaxwellBiosci, on how their research could transform health and longevity.

Imagine a world where aging is reversible. CEO Scotch McClure explains how @MaxwellBiosci is pushing the boundaries of science to make it happen. Watch the full interview here:

Scotch McClure from @MaxwellBiosci discusses reversing aging, pathogen-fighting peptides, and their implications for human health in our latest interview:

Is aging contagious? Our latest interview with Scotch McClure, CEO of @MaxwellBiosci, explores groundbreaking theories that could reshape how we think about aging and health. Watch now on our website

In a powerful interview with @BostonMagazine, actress @elizadushku shares her transformative journey with psychedelic-assisted therapy:

Mindstate Design Labs AI-Designed Trial Gets FDA Approval Mindstate Design Labs has announced major news, receiving both FDA and European Medicines Agency (EMA) approval to commence human trials of its compound, MSD-001. https://t.co/ELHtCCOJ6z

Psyence Biomed Announces Acquisition of Psilocybin Drug Developer Clairvoyant Therapeutics Clairvoyant is running a Phase IIb clinical trial evaluating synthetic psilocybin for Alcohol Use Disorder (AUD) https://t.co/AW3p9LKYgx

The FDA panel has rejected the first MDMA treatment for PTSD, citing serious concerns about the quality and reliability of the clinical trials conducted. https://t.co/u2VWCLImzW

We recently sat down with @neonneurons, CEO of @TerranBio, to discuss the exciting developments in their pipeline, particularly their latest schizophrenia therapeutic, TerXT. Read the full interview here:

In a new study, researchers from the Centre for Psychedelic Research at @imperialcollege found that on average, people reported improvements across a range of areas of sexual function up to six months after their psychedelic experience, including their enjoyment of sex, sexual

Big News as MAPS PBC Rebrands to Lykos Therapeutics; Closes $100m Series A Funding https://t.co/MsZdQvLK8J

Atai Life Sciences Invests $50 Million into Beckley Psytech. The investment gives atai a 35.5% ownership share and exposure to Beckley's advanced trials. https://t.co/l9cMeUl181

Microdose takes a look at the top psychedelic stories of 2023. Including: - Australia Legalization - Government Support for Psychedelics - MindMed's Phase 2b LSD Trial - Cybin's Phase 2 Trials for Depression - MAPS New Drug Application With FDA https://t.co/seWQzH6h3U

We take a deeper look at ancient shamanic traditions, exploring how magic mushrooms may be a part of Christmas history https://t.co/Our5Ozkfp8

Awakn signs global licensing agreement for exclusivity of proprietary S-ketamine oral film formulation $AWKN https://t.co/yFSjcaS5Iy

Terran Biosciences Receives FDA Clearance for MRI Scan Technology Terran gets FDA approval for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI https://t.co/ahgk5Ka13s